-+ 0.00%
-+ 0.00%
-+ 0.00%

Kala Bio faces Nasdaq delisting after stock trades below $1 for 30 days

PUBT·08/28/2026 10:47:04
Listen to the news
Kala Bio faces Nasdaq delisting after stock trades below $1 for 30 days
  • Kala Bio received a Nasdaq staff determination letter on Aug. 27, 2026 for failing the $1 minimum bid price rule.
  • Shares closed below $1 for 30 consecutive business days from July 16, 2026 through Aug. 26, 2026.
  • Nasdaq denied the standard 180-day cure period because the company completed a 1-for-50 reverse split on May 11, 2026.
  • A hearing request to the Nasdaq Hearings Panel is planned; a timely filing would stay suspension or delisting pending a decision.
  • Continued listing remains uncertain, raising delisting risk from the Nasdaq Capital Market.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kala Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001829126-26-009454), on August 28, 2026, and is solely responsible for the information contained therein.